<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01468766</url>
  </required_header>
  <id_info>
    <org_study_id>BEST</org_study_id>
    <nct_id>NCT01468766</nct_id>
  </id_info>
  <brief_title>Effects of a Supervised Progressive Resistance Training With Breast Cancer Patients During Adjuvant Radiotherapy</brief_title>
  <acronym>BEST</acronym>
  <official_title>Effects of a Supervised Progressive Resistance Training With Breast Cancer Patients During Adjuvant Radiotherapy - A Randomised Controlled Intervention Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Tumor Diseases, Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>German Cancer Research Center</source>
  <brief_summary>
    <textblock>
      The purpose of this randomized intervention study is to investigate the effects and
      biological mechanisms of a supervised 12-week progressive resistance training on fatigue and
      immunological and inflammatory biomarkers in breast cancer patients during adjuvant
      radiotherapy. To determine the effect of the exercise itself beyond potential psychosocial
      effects due to attention by trainers or the group support, patients in the control group have
      a comparable training schedule (i.e. 60 min, twice a week, for 12 weeks) but with relaxation
      training (Jacobsen method).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fatigue measured by Fatigue Assessment Questionnaire (FAQ)</measure>
    <time_frame>change between baseline and week 13 (end of intervention)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantity of FoxP3+ CD25+ regulatory T-cells</measure>
    <time_frame>change between baseline and week 13 (end of intervention)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory parameter CRP, SAA and IL-6</measure>
    <time_frame>change between baseline and week 13 (end of intervention)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating lymphocytes subpopulations (CD4+, CD8+, CD56+)</measure>
    <time_frame>change between baseline and week 13 (end of intervention)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of FoxP3+ CD25+ regulatory T-cells (in a subgroup only)</measure>
    <time_frame>change between baseline and week 13 (end of intervention)</time_frame>
    <description>immunmagnetic purification of the Treg (Selection by CD4 und CD25 expression; MACS-beads) by co-culturing of titrated Treg with 3H marked autologuous, polyclonal (anti CD3/CD28) activiated, conventional T-cells (CD4+, CD25+) and subsequent assessment of the proliferation of conventional T-cells.
Zur Bestimmung der Treg-Spezifität wurde eigens eine neue Methode entwickelt, die auf der signifikant erhöhten suppressiven Aktivität antigenspezifisch aktivierter Treg, gegenüber nicht aktivierten Treg, basiert.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life measured by the European Organisation for Research and Treatment of Cancer questionnaire (EORTC-QLQ30/BR23)</measure>
    <time_frame>change between baseline and week 13 (end of intervention)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression measured by &quot;Allgemeine Depressionsskala&quot; (ADS, the German version of the Center for Epidemiological Studies Depression Scale (CES-D))</measure>
    <time_frame>change between baseline and week 13 (end of intervention)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength measured at the IsoMed2000®</measure>
    <time_frame>change between baseline and week 13 (end of intervention)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiorespiratory fitness measured by ergospirometry</measure>
    <time_frame>change between baseline and week 13 (end of intervention)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with lymphedema, pain, nausea, dyspnea, or tachycardia as a measure of safety of resistance training during radiotherapy.</measure>
    <time_frame>events with onset or worsening during the 12-week intervention period are considered</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive performance measured by the Trail-Making-Test</measure>
    <time_frame>change between baseline and week 13 (end of intervention)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity of radiotherapy (acute radio dermatitis; LENT-SOMA classification for late effects)</measure>
    <time_frame>acute toxicity during radio therapy and late effects 6 weeks after end of radio therapy are recorded</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Cancer-related Fatigue</condition>
  <arm_group>
    <arm_group_label>Resistance training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Relaxation training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Supervised progressive resistance training</intervention_name>
    <description>2x60 minutes per week for 12 weeks</description>
    <arm_group_label>Resistance training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Supervised progressive muscle relaxation training (Jacobson method)</intervention_name>
    <description>2x60 minutes per week for 12 weeks</description>
    <arm_group_label>Relaxation training</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed primary breast cancer, stage I-III, after lumpectomy or
             mastectomy, indication for adjuvant radiotherapy

          -  BMI: 18-40

          -  ability to understand and follow the study protocol

        Exclusion Criteria:

          -  contraindication for exercise

          -  participation in the BEATE trial or another systematic resistance or relaxation
             training
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Steindorf, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>German Cancer Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Karin Potthoff, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Center for Tumor Diseases</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Potthoff K, Schmidt ME, Wiskemann J, Hof H, Klassen O, Habermann N, Beckhove P, Debus J, Ulrich CM, Steindorf K. Randomized controlled trial to evaluate the effects of progressive resistance training compared to progressive muscle relaxation in breast cancer patients undergoing adjuvant radiotherapy: the BEST study. BMC Cancer. 2013 Mar 28;13:162. doi: 10.1186/1471-2407-13-162.</citation>
    <PMID>23537231</PMID>
  </reference>
  <results_reference>
    <citation>Steindorf K, Schmidt ME, Klassen O, Ulrich CM, Oelmann J, Habermann N, Beckhove P, Owen R, Debus J, Wiskemann J, Potthoff K. Randomized, controlled trial of resistance training in breast cancer patients receiving adjuvant radiotherapy: results on cancer-related fatigue and quality of life. Ann Oncol. 2014 Nov;25(11):2237-43. doi: 10.1093/annonc/mdu374. Epub 2014 Aug 5.</citation>
    <PMID>25096607</PMID>
  </results_reference>
  <results_reference>
    <citation>Klassen O, Schmidt ME, Scharhag-Rosenberger F, Sorkin M, Ulrich CM, Schneeweiss A, Potthoff K, Steindorf K, Wiskemann J. Cardiorespiratory fitness in breast cancer patients undergoing adjuvant therapy. Acta Oncol. 2014 Oct;53(10):1356-65. doi: 10.3109/0284186X.2014.899435. Epub 2014 May 16.</citation>
    <PMID>24837860</PMID>
  </results_reference>
  <results_reference>
    <citation>Schmidt ME, Meynköhn A, Habermann N, Wiskemann J, Oelmann J, Hof H, Wessels S, Klassen O, Debus J, Potthoff K, Steindorf K, Ulrich CM. Resistance Exercise and Inflammation in Breast Cancer Patients Undergoing Adjuvant Radiation Therapy: Mediation Analysis From a Randomized, Controlled Intervention Trial. Int J Radiat Oncol Biol Phys. 2016 Feb 1;94(2):329-37. doi: 10.1016/j.ijrobp.2015.10.058. Epub 2015 Nov 2.</citation>
    <PMID>26853341</PMID>
  </results_reference>
  <results_reference>
    <citation>Gollhofer SM, Wiskemann J, Schmidt ME, Klassen O, Ulrich CM, Oelmann J, Hof H, Potthoff K, Steindorf K. Factors influencing participation in a randomized controlled resistance exercise intervention study in breast cancer patients during radiotherapy. BMC Cancer. 2015 Mar 27;15:186. doi: 10.1186/s12885-015-1213-1.</citation>
    <PMID>25885634</PMID>
  </results_reference>
  <results_reference>
    <citation>Scharhag-Rosenberger F, Kuehl R, Klassen O, Schommer K, Schmidt ME, Ulrich CM, Wiskemann J, Steindorf K. Exercise training intensity prescription in breast cancer survivors: validity of current practice and specific recommendations. J Cancer Surviv. 2015 Dec;9(4):612-9. doi: 10.1007/s11764-015-0437-z. Epub 2015 Feb 26.</citation>
    <PMID>25711667</PMID>
  </results_reference>
  <results_reference>
    <citation>Schmidt ME, Semik J, Habermann N, Wiskemann J, Ulrich CM, Steindorf K. Cancer-related fatigue shows a stable association with diurnal cortisol dysregulation in breast cancer patients. Brain Behav Immun. 2016 Feb;52:98-105. doi: 10.1016/j.bbi.2015.10.005. Epub 2015 Oct 9.</citation>
    <PMID>26456694</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 11, 2011</study_first_submitted>
  <study_first_submitted_qc>November 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 9, 2011</study_first_posted>
  <last_update_submitted>April 18, 2016</last_update_submitted>
  <last_update_submitted_qc>April 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>German Cancer Research Center</investigator_affiliation>
    <investigator_full_name>Karen Steindorf</investigator_full_name>
    <investigator_title>Prof. Dr. Karen Steindorf / Dr. Karin Potthoff, National Center for Tumor Diseases, Heidelberg</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

